Evidence map›Paper›PMID 40159706›Full record

ArticleTherapeutic delivery2025

Pharmacokinetic assessment and level-A IVIVC establishment of rifampicin-loaded 3D printed tablets using SLS 3D printing.

Tukaram Karanwad, Dimple S Lalchandani, Sachin B Jorvekar, Santa Mandal, Pawan Kumar Porwal, Roshan M Borkar, Subham Banerjee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tukaram KaranwadDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Changsari, India.
Dimple S LalchandaniDepartment of Pharmaceutical Analysis, NIPER-Guwahati, Changsari, India.
Sachin B JorvekarDepartment of Pharmaceutical Analysis, NIPER-Guwahati, Changsari, India.
Santa MandalFaculty of Pharmaceutical Science, Assam down town University, Guwahati, India.
Pawan Kumar PorwalDepartment of Pharmaceutical Analysis, NIPER-Guwahati, Changsari, India.
Roshan M BorkarDepartment of Pharmaceutical Analysis, NIPER-Guwahati, Changsari, India.
Subham BanerjeeDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Changsari, India.ORCID 0000-0002-2984-1159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study investigated the

methods

resultsIn the acidic medium, 16.22% of RIF was released within the first 2 h, whereas in the alkaline medium, the release increased to 41.75%, indicating a sustained release from the sintered 3D printed tablets. Pharmacokinetic parameters and their corresponding values of

conclusionThe results underscore the potential of SLS 3DP technology in advancing the development of RIF-containing 3D printed tablets by sustaining

Indexed as

Antibiotics, AntitubercularPrinting, Three-DimensionalRifampinAnimalsDelayed-Action PreparationsDrug CompoundingDrug LiberationHydrogen-Ion ConcentrationMaleRabbitsSolubilityTabletsTandem Mass SpectrometryAntibiotics, AntitubercularDelayed-Action PreparationsRifampinTablets3D printed tabletsIVIVCLC-ESI-MS/MSRIFSLS

Identifiers

PMID40159706
PMCPMC12140464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.